Datapoint: Arcutis Scores New Indication for Zoryve

The FDA approved a new drug concentration and a new indication to Arcutis Biotherapeutics, Inc.’s Zoryve (roflumilast) 0.15% cream for the treatment of mild to moderate atopic dermatitis in people at least 6 years old. The agency initially approved the first topical PDE4 inhibitor on July 29, 2022. It remains available as a 0.3% cream and a foam. The topical was first approved in 2011 for the treatment of psoriasis, an indication for which it currently holds covered or better status for 70% of all insured lives under the pharmacy benefit.

SOURCE: MMIT Analytics, as of 7/17/24

0 Comments
© 2025 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 17

Datapoint: Michigan Awards Contracts for New Duals Program

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 16

Datapoint: CMS Releases 2025 Star Ratings

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
October 15

Datapoint: Pfizer Scores Another Hemophilia Nod

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today